Akebia Therapeutics, Inc. (AKBA): Price and Financial Metrics


Akebia Therapeutics, Inc. (AKBA)

Today's Latest Price: $10.98 USD

0.08 (-0.72%)

Updated Aug 7 12:00am

Add AKBA to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 344 in Biotech

See all "A" rated Strong Buy stocks

AKBA Stock Summary

  • Of note is the ratio of Akebia Therapeutics Inc's sales and general administrative expense to its total operating expenses; merely 17.51% of US stocks have a lower such ratio.
  • With a year-over-year growth in debt of 226.73%, Akebia Therapeutics Inc's debt growth rate surpasses 93.4% of about US stocks.
  • Revenue growth over the past 12 months for Akebia Therapeutics Inc comes in at 49.61%, a number that bests 89.7% of the US stocks we're tracking.
  • Stocks that are quantitatively similar to AKBA, based on their financial statements, market capitalization, and price volatility, are ONTX, INFI, ADXS, IPHA, and VNE.
  • AKBA's SEC filings can be seen here. And to visit Akebia Therapeutics Inc's official web site, go to www.akebia.com.
AKBA Daily Price Range
AKBA 52-Week Price Range

AKBA Stock Price Chart Technical Analysis Charts


AKBA Price/Volume Stats

Current price $10.98 52-week high $13.71
Prev. close $11.06 52-week low $2.99
Day low $10.93 Volume 920,900
Day high $11.57 Avg. volume 1,537,712
50-day MA $12.04 Dividend yield N/A
200-day MA $8.49 Market Cap 1.43B

Akebia Therapeutics, Inc. (AKBA) Company Bio


Akebia Therapeutics focuses on the development and commercialization of proprietary therapeutics based on hypoxia inducible factor (HIF) biology for patients with kidney disease. The company was founded in 2007 and is based in Cambridge, Massachusetts.





AKBA Latest News Stream


Event/Time News Detail
Loading, please wait...

AKBA Latest Social Stream


Loading social stream, please wait...

View Full AKBA Social Stream

Latest AKBA News From Around the Web

Below are the latest news stories about Akebia Therapeutics Inc that investors may wish to consider to help them evaluate AKBA as an investment opportunity.

Akebia launches vadadustat study in COVID-19 complication

Akebia Therapeutics ([[AKBA]] -0.2%) has initiated an investigator-sponsored study evaluating the use of vadadustat, an investigational oral hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI), as a potential therapy to prevent and lessen the severity of acute respiratory distress syndrome ((ARDS)), a complication of COVID-19 infection. The study will enroll up to...

Seeking Alpha | July 14, 2020

Akebia Initiates Vadadustat Study In Covid-19 Patients

Akebia Therapeutics (AKBA) has announced the initiation of an investigator-sponsored study evaluating the use of vadadustat as a potential therapy to prevent and … The post Akebia Initiates Vadadustat Study In Covid-19 Patients appeared first on Smarter Analyst .

Smarter Analyst | July 14, 2020

Akebia launches vadadustat study in COVID-19 complication (NASDAQ:AKBA)

Akebia Therapeutics (AKBA -0.2%) has initiated an investigator-sponsored study evaluating the use of vadadustat, an investigational oral hypoxia-inducible

Seeking Alpha | July 14, 2020

Akebia Announces Initiation of Investigator-Sponsored Study Evaluating Vadadustat for Prevention and Treatment of ARDS in Patients Hospitalized with COVID-19

Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose of bettering the lives of people impacted by kidney disease, today announced the initiation of an investigator-sponsored study evaluating the use of vadadustat, Akebia's investigational oral hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI), as a potential therapy to prevent and lessen the severity of acute respiratory distress syndrome (ARDS), a complication of COVID-19 infection. The study will be conducted by The University of Texas Health Science Center at Houston (UTHealth) in Houston, Texas. Bentley J. Bobrow, MD, Chair of Emergency Medicine, and Holger K. Eltzschig, MD, PhD, Chair of the Department of Anesthesiology with McGovern Medical School at UTHealth, will serve as co-pr...

Yahoo | July 14, 2020

The Daily Biotech Pulse: Intersect ENT Jumps On M&A Speculation, VIVUS Files For Bankruptcy

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 7) AbbVie Inc (NYSE: ABBV ) ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD ) Akebia Therapeutics Inc (NASDAQ: AKBA ) Akero Therapeutics Inc (NASDAQ: AKRO ) Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY ) argenx SE – ADR (NASDAQ: ARGX ) BioMarin Pharmaceutical Inc. (NASDAQ: BMRN ) Biondvax Pharmaceuticals Ltd – ADR (NASDAQ: BVXV ) BioSpecifics Technologies Corp. (NASDAQ: BSTC ) (FDA approved the cellulitis drug it had licensed to Endo International PLC (NASDAQ: ENDP )) Cerus Corporation (NASDAQ: CERS ) (announced study results demonstrating that its INTERCEPT Blood System inactivates SARS-CoV-2 in plasma components intended for transfusion) Corvus Pharma...

Benzinga | July 8, 2020

Read More 'AKBA' Stories Here

AKBA Price Returns

1-mo -12.12%
3-mo -8.35%
6-mo 22.00%
1-year 148.98%
3-year -21.29%
5-year 14.14%
YTD 73.73%
2019 14.29%
2018 -62.81%
2017 42.84%
2016 -19.43%
2015 11.00%

Continue Researching AKBA

Here are a few links from around the web to help you further your research on Akebia Therapeutics Inc's stock as an investment opportunity:

Akebia Therapeutics Inc (AKBA) Stock Price | Nasdaq
Akebia Therapeutics Inc (AKBA) Stock Quote, History and News - Yahoo Finance
Akebia Therapeutics Inc (AKBA) Stock Price and Basic Information | MarketWatch


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.8714 seconds.